Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelagliptin QOL Evaluation in Type 2 Diabetes Mellitus
jRCT1080223427Phase 4
- Sponsor
- Takeda
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Quality of life measured by DTR-QOL.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080223427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223427.